Person: KARAALP, ATİLA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARAALP
First Name
ATİLA
Name
5 results
Search Results
Now showing 1 - 5 of 5
Publication Open Access COLCHICINE USE DURING PREGNANCY: CASE REPORTS(BMJ PUBLISHING GROUP, 2019-06) KARAALP, ATİLA; Duman, Nesrin Caglayan; Karabacak, Murat; Oglu, Medine Gulcebi Idriz; Inanc, Nevsun; Asik, Zehra Nur Turgan; Atagunduz, Pamir; Ozkula, Songul; Gulhan, Rezzan; Goren, Zafer; Onat, Filiz; Direskeneli, Haner; Karaalp, AtilaPublication Metadata only Potential drug-drug interactions in a medical intensive care unit of a university hospital(TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY, 2016) KARAALP, ATİLA; Gulcebi Idriz Oglu, Medine; Kucukibrahimoglu, Esra; Karaalp, Atila; Sarikaya, Ozlem; Demirkapu, Mahluga; Onat, Filiz; Goren, Mehmet ZaferBackground/aim: Drug-drug interactions (DDIs) can impact patient safety. Occurrence of clinically important DDIs is higher for intensive care unit (ICU) patients. This observational study aimed to evaluate the potential DDIs in medical ICU patients of a university hospital. Materials and methods: The Medical Pharmacology Department organized consultation reports for ICU patients in order to detect the DDIs. To focus on clinically important DDIs, interactions in the C, D, or X risk rating categories of the Lexi-Interact online database were analyzed. Frequency and clinical risk rating categories of DDIs were detected. Relationship between number of prescriptions and DDIs were assessed. The most frequent drug/drug groups were identified. Results: Of 101 ICU patients, 45.5% were found to have DDIs. We detected 125 C (72.2%), 37 D (21.4%), and 11 X (6.4%) risk category interactions. A statistically significant increase in the number of DDIs was shown with the number of prescriptions (P = 0.002). The most frequent DDIs were between agents acting on the cardiovascular system and corticosteroids (12.8%). Conclusion: Results of this study show that pharmacological consultation plays a critical role in the recognition of DDIs for improvement of medication management and effective therapeutic endpoints without any adverse or toxic reactions.Publication Metadata only p353 Evalution of antiepileptic drug use in the pregnant patients with epilepsy in a university hospital in Istanbul(2014-07-03) GÜLÇEBİ İDRİZ OĞLU, MEDİNE; GÜLHAN, REZZAN; KARAALP, ATİLA; GÖREN, MEHMET ZAFER; ONAT, FİLİZ; GÜLÇEBİ İDRİZ OĞLU M., Küçükibrahimoğlu E., JAFAROVA DEMİRKAPU M., GÜLHAN R., KARAALP A., GÖREN M. Z., ONAT F.Publication Metadata only Therapeutic drug monitoring of immunosuppressant drugs in Marmara University Hospital(LIPPINCOTT WILLIAMS & WILKINS, 2004) AKICI, AHMET; Karaalp, A; Demir, D; Goren, MZ; Akici, A; Iskender, E; Yananli, HR; Ozyurt, H; Ozkaynakci, A; Berkman, K; Oktay, S; Onat, FImmunosuppressive therapy is the most crucial treatment of organ-transplanted patients. Both cyclosporin and tacrolimus have become a part of the standard immunosuppressive therapy for prevention of rejection. However, lower levels of these drugs are associated with insufficient therapy and eventually result in rejection of the organ, and, on the contrary, higher levels are associated with toxicity to certain organs such as liver and kidneys. Therefore, the levels of these drugs in body fluids should be monitored for the prevention of unwanted situations. In this retrospective study, the authors evaluated the 18-month profile of blood drug concentrations of cyclosporin and tacrolimus in patients admitted to the TDM Unit of the Marmara University Hospital (Istanbul, Turkey) between June 2000 and November 2001. A total of 578 blood samples (347 cyclosporin and 231 tacrolimus) from 134 patients (88 for cyclosporin, 46 for tacrolimus) were evaluated in this period. The therapeutic trough ranges were accepted as 100-350 ng/mL for cyclosporin and 5 20 ng/mL for tacrolimus, and levels below or above the identified levels were accepted to be subtherapeutic or toxic. Most of the results were found within the range of therapeutic levels (67.48% for cyclosporin and 82.71% for tacrolimus). Subtherapeutic levels were found in 19.92% of all cyclosporin and 10.53% of all tacrolimus assays, whereas toxic levels were seen in 12.60% and 6.77% of cyclosporin and tacrolimus results, respectively. In conclusion, this study gives information about the TDM practice in institutional clinical laboratory and also indicates the importance of critical information such as sampling time for individual decision making in dosage regiment.Publication Metadata only Potential drug interactions with antiepileptics in the intensive care unit patients of a university hospital(2015-02-01) GÜLÇEBİ İDRİZ OĞLU, MEDİNE; GÜLHAN, REZZAN; KARAALP, ATİLA; GÖREN, MEHMET ZAFER; ONAT, FİLİZ; GÜLÇEBİ İDRİZ OĞLU M., Duman N., GÜLHAN R., KARAALP A., GÖREN M. Z. , ONAT F.